| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
|
N Engl J Med
|
2015
|
6.38
|
|
2
|
The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide.
|
Science
|
2013
|
4.60
|
|
3
|
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
|
J Clin Oncol
|
2005
|
3.44
|
|
4
|
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
|
J Natl Cancer Inst
|
2008
|
3.21
|
|
5
|
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
|
Science
|
2015
|
3.12
|
|
6
|
Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.
|
J Clin Oncol
|
2002
|
2.87
|
|
7
|
Palbociclib and Letrozole in Advanced Breast Cancer.
|
N Engl J Med
|
2016
|
2.37
|
|
8
|
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
|
Cancer
|
2007
|
1.53
|
|
9
|
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
|
Lancet Oncol
|
2016
|
1.41
|
|
10
|
Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
|
Br J Cancer
|
1996
|
1.40
|
|
11
|
Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors.
|
Cancer Res
|
2010
|
1.37
|
|
12
|
In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients.
|
Clin Cancer Res
|
1998
|
1.31
|
|
13
|
Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels.
|
Clin Cancer Res
|
2008
|
1.11
|
|
14
|
Cancer and the gut microbiota: an unexpected link.
|
Sci Transl Med
|
2015
|
1.08
|
|
15
|
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade.
|
Immunity
|
2016
|
1.07
|
|
16
|
Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer.
|
Clin Cancer Res
|
2001
|
1.05
|
|
17
|
NeoPalAna: Neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor positive breast cancer.
|
Clin Cancer Res
|
2017
|
1.03
|
|
18
|
Parietal cell protein kinases. Selective activation of type I cAMP-dependent protein kinase by histamine.
|
J Biol Chem
|
1985
|
1.00
|
|
19
|
CDK4/6 inhibition triggers anti-tumour immunity.
|
Nature
|
2017
|
0.99
|
|
20
|
Feasibility of MR metabolomics for immediate analysis of resection margins during breast cancer surgery.
|
PLoS One
|
2013
|
0.85
|
|
21
|
CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer.
|
Cancer Discov
|
2016
|
0.83
|
|
22
|
Presurgical (neoadjuvant) endocrine therapy is a useful model to predict response and outcome to endocrine treatment in breast cancer patients.
|
J Steroid Biochem Mol Biol
|
2011
|
0.80
|
|
23
|
CDK4/6 inhibitors in luminal breast cancer.
|
Lancet Oncol
|
2014
|
0.75
|
|
24
|
CDK4/6 inhibitors in breast cancer: a role in triple-negative disease?
|
Lancet Oncol
|
2019
|
0.75
|
|
25
|
A surprising finding by a surgery for lumbar intervertebral disk herniation--Ewing's sarcoma.
|
Acta Univ Palacki Olomuc Fac Med
|
1987
|
0.75
|